(!300-400/mL) have an impaired antibody response after rabies postexposure prophylaxis that uses tissue-culture rabies vaccines [1, 2] . The World Health Organization (WHO) Expert Committee on Rabies recommends the use of a double dose of rabies vaccine, given at different sites, for immunocompromised people (including HIV-infected patients) who have been potentially exposed to rabies. However, limited evidence indicates that this dose will mount an adequate rabies neutralizing antibody (Nab) response [3, 4] . Nevertheless, we followed this regimen of postexposure treatment for HIV-infected people with possible or proven rabies exposure at our institute. Further studies are needed to determine whether this procedure results in an Nab titer above the minimal WHO recommended level of 0.5 IU/mL for rabies protection [5] .
Four-site intradermal (id) rabies vaccination is associated with higher rabies Nab response and induces earlier and stronger specific cell-mediated immune responses than does the full-dose intramuscularly administered regimen [6, 7] . We conducted a prospective study of the Nab response to evaluate the immunogenicity after 4-site id postexposure rabies vaccination in HIV-infected persons (doubling the id doses of cellculture rabies vaccine in 2-2-2-0-1-1 regimen as recommended by the WHO).
Queen Saovabha Memorial Institute is the regional referral center for rabies postexposure treatment in Bangkok, Thailand. Approximately 6000 rabies-exposed patients are treated yearly at this institute. We assessed rabies-exposed patients with risk factors for HIV infection and invited them to participate in this study. These patients were counseled, and their permission was obtained to confirm the diagnosis of HIV infection by ELISA. If the test was positive, they were eligible for the study. The ethics committee of our institution approved this study.
During the 1-year study period (June 1998-May 1999), 10 HIV-infected patients (age range, 7-43 years) without signs of active opportunistic infections who presented with possible or proven rabies exposure were enrolled (table 1). Nine patients had severe exposure (WHO category III), and 1 patient had WHO category II exposure [5] . All 10 patients had a history of HIV-related conditions, such as oral candidiasis, oral hairy leukoplakia, herpes zoster, pulmonary tuberculosis, and cerebral toxoplasmosis. Only 4 patients were receiving 2-3 antiretroviral drugs. Patient 1 (rabies exposure WHO category II) had received preexposure rabies vaccination with human diploid cell vaccine 2 years ago. All patients were given the postexposure rabies prophylaxis as recommended by WHO guidelines [5] . They received the 4-site id postexposure regimen (4-4-4-0-2-2) with purified Vero cell rabies vaccine (doubling the id doses of cell-culture rabies vaccine in 2-2-2-0-1-1 regimen as recommended by the WHO).
Purified Vero rabies vaccine (Institute Mérieux; commercial lot 509-1) has a potency of 7.4 IU per ampule and contains 0.5 mL of the diluent volume. Patients were given vaccine dosing of 0.1 mL of purified Vero rabies vaccine (one-fifth of the diluent volume per dose) id at 4 sites (deltoids and anterior thighs) on days 0, 3, and 7, and at 2 sites on days 30 and 90. Nine patients with severe bite wounds (WHO category III) received human rabies immunoglobulin (batch L 39058; potency 1150 IU/mL) administered as 20 IU/kg body weight, as recommended by the WHO. Immunoglobulin was adequately infiltrated around the wound, and the remaining dose was given via deep intramuscular injection into the gluteal region. Blood samples were obtained from each subject immediately before vaccination (day 0) and on days 7, 14, 30, and 90 after vaccination. CD4 ϩ T lymphocyte counts were determined in venous blood collected from all patients before vaccination. All serum samples were quantitatively tested for rabies Nab by use of the rapid focus fluorescent inhibition test [8] . Nab titers of у0.5 IU/mL were considered to be an acceptable antibody response for protection against rabies [5] . Informed consent was obtained from each subject after the nature of the study protocols had been fully explained. There were no deaths as a result of rabies during the next 3 months. Three of 7 HIVinfected patients with CD4 ϩ T lymphocyte counts of р200/mL (range, 25-199/mL) had a poor or even undetectable Nab response to vaccination (table 1) . They had Nab titers less than the minimal WHO-recommended level of 0.5 IU/mL on day 14 after vaccination. HIV-infected patients with higher CD4 ϩ T lymphocyte counts had good antibody responses to postexposure rabies vaccination. Previous studies demonstrated that HIV-infected patients with low CD4 ϩ T lymphocyte counts had a poor or even undetectable Nab response to pre-or postexposure rabies vaccination with cell-culture rabies vaccine as recommended by the WHO [1, 2, 9] . The WHO Expert Committee on Rabies recommends the use of a double-dose volume of rabies vaccine in HIV-infected patients potentially exposed to the rabies virus, although such use has little scientific evidence backing it [3] . We followed this recommendation in our clinic and paid particular attention to wound cleansing and careful determination of Nab titers to ensure that an acceptable antibody response developed in HIV-infected patients who needed postexposure rabies vaccination [10] . Although 4-site id rabies vaccination (doubling the id doses of cell-culture vaccine) induced significantly higher titers of Nab to rabies virus than did the im vaccination used in previous studies, HIV-infected patients with CD4 ϩ T lymphocyte counts !200/mL did not respond well to 4-site id vaccination [6, 7] . Failure of rabies Nab response in HIV-infected people with low CD4 ϩ T lymphocyte counts is the reason we continue to assess Nab titers after postexposure vaccination in patients with AIDS. If an acceptable antibody response is not achieved, a second double-dose series of rabies vaccine should be given to successfully mount an adequate antibody response in the patient [4] . At present, cleansing the wound, vigorous wound injection with immunoglobulin (to neutralize the virus at the inoculation site), and determination of antibody response in HIV-infected patients after postexposure rabies vaccination are the most important postexposure measures that can be offered to HIV-infected and severely rabies-exposed patients (WHO category 111) [1] [2] [3] [4] . Research is urgently needed into administering frequent booster injections, increasing the dose volume of vaccine administered either im or id, or using sequential doses of immunoglobulin for HIV-infected patients with low CD4 ϩ T lymphocyte counts who have unacceptable Nab responses to postexposure vaccination.
